Citius Pharma Q1 net loss $9.2M; cash runway through Aug 2024

Citius Pharmaceuticals, Inc.

2025-Q1 EPS reported -$1.45 vs consensus -$0.39 ▼ miss (-270.8%)

Net loss of $9.2M ($0.06 per share) compared to loss of $3.6M ($0.02 per share) in prior year.
Cash and equivalents $20.3M as of Dec 31, 2023; runway expected through August 2024.
LYMPHIR BLA resubmitted to FDA; awaiting PDUFA date; merger of oncology subsidiary with TenX (TENK) expected H1 2024.
Completed enrollment in Mino-Lok Phase 3 trial; topline results expected in Q2 2024.
R&D expenses $2.6M (down from $3.4M); G&A expenses $3.7M (up from $2.6M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Citius Pharmaceuticals, Inc. reported first quarter of fiscal 2024 results: net income $9.2 million, or ($0.06) per share, EPS ($0.06) per share.

Period: first quarter of fiscal 2024
Net income: $9.2 million, or ($0.06) per share
EPS: ($0.06) per share
Result: reported results

Exact text from the filing

On February 14, 2024, we issued a press release announcing our results of operations for the first quarter of fiscal 2024.

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-014332

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.